-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies have shown that meningitis B vaccines such as Bexsero may provide some protection against gonorrhea. GlaxoSmithKline (GSK) is currently evaluating whether to conduct some clinical trials of Bexsero in gonorrhea.
gonorrhea is a sexually transmitted disease caused by gonorrhea neccobacteria ,called gonorrhea, which is mainly transmitted through sexual activity and intimate contact. In recent years, the incidence of gonorrhea has increased significantly. Due to antibiotic resistance, the treatment of gonorrhea has become increasingly difficult clinically, and an effective preventive vaccine is urgently needed in this area. In the United States, the number of reported gonorrhea cases increased by 18.6 percent in 2017, according to the U.S. Centers for Disease Control and Prevention (CDC).
, a retrospective study in New Zealand found that MeNZB, GSK's other meningitis B vaccine, provides some protection against the spread of gonorrhea. For the study, researchers analyzed large-scale MeNZB vaccination data and found that the vaccine was 31 percent effective at preventing gonorrhea infections.
"It's good, but it's not the best, and we want the vaccine to be about 90 percent effective," Emmanuel Hanon, GSK's head of vaccine research and development, told Bloomberg.
GSK's Bexsero contains the same ingredients as MeNZB, as well as three additional antigens for more meningococcal serum group B (MenB) strains.
GSK spokesman said the company is weighing whether the vaccine Bexsero can prevent gonorrhea and is working with regulators and researchers to assess what more needs to be done to prevent gonorrhea. As the work is still under exploration, it would be inconvenient to comment further.
, GSK had not conducted any tests in the field of gonorrhea prevention, and the company is currently exploring how to extend its expertise in vaccines to the important issue of prevention of gonorrhea.
Bexsero was developed by Novartis, and GlaxoSmithKline acquired Novartis' vaccine business in 2014 as part of its asset replacement. Bexsero has been strong in GSK's vaccine business, generating 470 million pounds ($600 million) in sales in the first nine months of 2018. (Bio Valley)
